| |
|
|
|
Nymox Pharmaceutical Corporation  
|
|
2.02 0.05 (0.03%) |
09-21 10:57 |
|
Open: |
1.96 |
Pre close: |
1.97 |
Target:
|
2.65
|
|
High: |
2.05 |
Low: |
1.96 |
Resistance:
|
2.27
2.65
|
|
Volume: |
39,967 |
Market Cap: |
166M |
Support:
|
1.91
 1.69
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
2.02
|
MACD |
MACD(12,26):
|
0.05  |
|
MA(20): |
2.08 |
Signal(12,26,9): |
0.08 |
|
MA(100): |
1.72 |
Stochastic Oscillator |
%K(14,3):
|
17.50 |
|
MA(250): |
2.12 |
%D(3): |
26.69 |
|
Average Volume(K) |
3-Month: |
1271855
|
52-Week |
High:
|
3.50 |
|
10-Days: |
15173 |
Low: |
1.25 |
|
RSI |
RSI(14):
|
52.11 |
Change(%): |
-19.3 |
|
Financials, Statistics and Valuation |
|
EPS |
-0.153 |
Return on Equity (ttm) |
-1618.2 |
Shares Out. (M) |
82.38 |
|
EPS Est. Current Year |
-0.200 |
Return on Assets (ttm) |
-298.3 |
Shares Float (M) |
44.89 |
|
EPS Est. Next Year |
-0.570 |
PEG Ratio |
0.00 |
% Held by Insiders |
44.97 |
|
EPS Est. Next Quarter |
0.000 |
Qtrly Rev. Growth |
0.0 |
% Held by Institutions |
6.93 |
|
Forward EPS |
-0.180 |
Gross Profit (p.s.) |
0.000 |
Shares Short (K) |
5070 |
|
Book Value (p.s.) |
-0.000 |
EBITDA (p.s.) |
-0.139 |
P/E |
-13.13 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
0.00 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-10.54 |
P/S |
0.00 |
|
Operating Margin |
0.00 |
Levered Free Cash Flow
(M) |
-6.22 |
P/CF |
-15.71 |
|
|
|
|
|
|
